Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088179 · ClinicalTrials.gov registry record · Phase 3
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Phase 3 study of Coronary Artery Disease, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,000
- Enrollment target
- 20
- Study locations
NCT00088179 is a Phase 3 study of Coronary Artery Disease that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 4,000 participants, above the 1,269-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (215% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00088179, a Phase 3 study of Coronary Artery Disease, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the study drug (pexelizumab), that blocks "complement activation," can reduce such side effects and be given safely to patients requiring the bypass procedure with the use of the heart-lung machine.
Conditions Studied
Interventions
- DRUG pexelizumab in conjunction with CABG
Study Locations (20)
Alabama
- Brookwood Medical Center - Birmingham
- Baptist Medical Center Princeton - Birmingham
- Baptist Health Systems Montclair - Birmingham
- Medical Center East Hospital - Birmingham
- University of Alabama at Birmingham Hospital - Birmingham
- Thomas Hospital - Fairhope
- Huntsville Hospital - Huntsville
- Mobile Infirmary Medical Center - Mobile
California
- Bakersfield Heart Hospital - Bakersfield
- Seaton Medical Center - Daly City
- Palomar Medical Center - Escondido
- Saddleback Memorial Medical Center - Laguna Hills
- Los Angeles County-University of Southern California Medical Center - Los Angeles
- University of Southern California University Hospital - Los Angeles
Arizona
- Banner Good Samaritan Medical Center - Phoenix
- Arizona Health Sciences Center - Tucson
- University Medical Center - Tucson
- Southern Arizona Veterans Affairs Health Care System - Tucson
Arkansas
- Sparks Regional Medical Center - Fort Smith
- Baptist Medical Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088179
The ClinicalTrials.gov registry entry for NCT00088179 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,269-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (215% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which pexelizumab in conjunction with CABG is the first listed.
NCT00088179 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00088179 about?
NCT00088179 is a clinical study titled "Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)". During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the st...
What is the current status of trial NCT00088179?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,000 participants. The study started on 2004-07. Estimated completion is 2005-10.
What conditions does trial NCT00088179 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00088179?
The interventions under investigation include: pexelizumab in conjunction with CABG (DRUG).
Who is sponsoring clinical trial NCT00088179?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00088179 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
RECRUITING · Phase 3
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.